Gates Foundation makes unusual investment in experimental cancer trial
The Bill & Melinda Gates Foundation is making an unusual investment in a biotech start-up’s experimental cancer trial, hoping that its novel technology will one day allow HIV patients to rebuild their immune systems.
Smart Immune, a French cell therapy company led by three female co-founders, has developed technology to coax stem cells, which have the ability to develop into many different cell types, into becoming immature “progenitor” T-cells in a lab. These are then injected into the body, where they mature into a crucial part of the immune system and learn to differentiate between normal cells and threats.
This story originally appeared on: Financial Times - Author:Hannah Kuchler
